CDK2 and metastatic neoplasm: Cox proportional hazard regression analysis of PFS according to the signatures of CDK6, p-CDK2 and cyclin E1 and clinicopathological parameters of the metastatic disease showed that the combined biomarkers signature was an independent prognostic factor of PFS in both tested cohorts (Supplementary Table 6).